Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Clinical Outcomes of Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell Patients With Pulmonary Hypertension

NCT03572036 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT03572036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03572036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Clinical Outcomes of Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell Patients With Pulmonary Hypertension
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Completed
Start date
June 20, 2018
Completion date
April 16, 2021
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension, sickle cell disease